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Diabetes mellitus (DM) constitutes a major end-stage renal
disease (ESRD) health problem. Glycemic control is
fundamental to the management of diabetes and its
complications, and relies on monitoring of hyperglycemia.
We therefore performed a primary data analysis of glycemic
control and survival on a large national ESRD database.
Ninety-five percent of patients with DM had type II diabetes
(N¼ 23 504), and five percent had type I diabetes (N¼ 1 371).
For the combined population, the mean hemoglobin A1c
(HgbA1c) was 6.77%, and the mean random blood glucose
was 168 mg/dl. Mean HgbA1c values were 47.0% in 35%
and 48.5% in 14%. Mean HgbA1c values were below 5%
in 11.3% of patients. Type I study patients tended to have
higher HgbA1c values. Most patients (75.8%) had three or
more random blood glucose determinations within 90 days
preceding the HgbA1c measurement. The HgbA1c showed
only a weak correlation with mean random glucose values
(R2 0.3716; s.e.¼ 1.36). The survival rates in the subsequent
12-month period ranged from 80 to 85% across different
HgbA1c strata. Kaplan–Meier survival curves grouped by
HgbA1c levels showed no correlation between HgbA1c and
survival at 12 months. More studies are needed to refine
recommendations for the role of HgbA1c and glycemic
control in this patient population.
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Patients with diabetes mellitus (DM) now account for 45 per
cent of the prevalent end-stage renal disease (ESRD)
population in the US, and the rate of ESRD caused by
diabetes increased 86% between 1993 and 2003.1 Most
incident patients with ESRD and diabetes carry multiple
chronic comorbid conditions such as ischemic heart disease,
congestive heart failure, and peripheral vascular disease when
they begin dialysis. Macrovascular complications, including
myocardial infarction, stroke, and peripheral vascular disease,
are the major causes of morbidity and mortality in patients
with ESRD and diabetes.
Although only a minority of patients with diabetes achieve
recommended goals for glycemic control,2–4 glycemic control
is fundamental to the management of diabetes5 and its
complications. Poor glycemic control is increasingly con-
sidered as an independent cardiovascular risk factor in
diabetes.4,6–9 Among patients with diabetes in a large
prospective study, high blood glucose concentrations were
associated with a greater incidence of cardiovascular
disease.10 Recent data suggest that glycosylated hemoglobin
levels are related to coronary heart disease risk in persons
with type I and II diabetes.11 In fact, chronic hyperglycemia
has been hypothesized to contribute to coronary disease in
individuals without diabetes as well.12,13 Limited data suggest
that poor glycemic control in patients with diabetes on
dialysis may be associated with increased morbidity from
diabetic vascular complications.14,15 Recent data demonstrate
that glycemic control may benefit patients with diabetes who
have established coronary disease.16,17 Epidemiologic studies
suggest the potential for improved glycemic control to reduce
cardiovascular complications in diabetes, hence the benefit of
hyperglycemia control on cardiovascular damage in patients
with diabetes continues to be studied.18,19 American Diabetes
Association (ADA) guidelines indicate that improved glyce-
mic control may lower the risk of myocardial infarction and
cardiovascular death.20 Among risk factor reductions for
mortality in dialysis patients with diabetes, improved
glycemic control is widely recommended.21 However,
whether glycemic control affects survival in diabetic ESRD
patients remains unclear.22 Monitoring of hyperglycemia is at
the center of management of diabetes.23,24 The hemoglobin
A1c (HgbA1c) concentration is a marker of hyperglycemia
and reflects average blood glucose concentration over
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3 months in diabetic individuals.25 HgbA1c tracks well in
individuals over time.26 The ADA recommends using point-
of-care glycohemoglobin (HgbA1c) values to track glycemic
control, make timely decisions on treatment, and to reduce
risks of adverse outcomes by lowering A1c levels to below
7%.27,28 However, less than half of patients with ESRD and
diabetes fulfill the recommendations of the ADA to undergo
at least four glycohemoglobin tests per year, and up to a
quarter receive no testing.1 Monitoring of capillary blood
glucose is also recommended, with a frequency and timing
dependent on the patient’s medical condition. However, half
of chronic kidney patients with diabetes have not had
glycosylated hemoglobin testing in the year before dialysis
initiation.29 Diabetic monitoring in the ESRD population is
also suboptimal, with over 60% not prescribed any diabetic
test strips and less than half receiving the four or more
HgbA1c tests per year recommended by the ADA1. The
apparent variability in HgbA1c testing practices in ESRD may
derive from the lack of consensus on HgbA1c testing to
reflect accurately glycemic control in ESRD patients with
diabetes,30,31 especially those on erythropoietin therapy.32
The relationship between glycosylated hemoglobin and
dialysis outcomes in DM has not been adequately characterized.
Actual levels of glycemic control are not reported in the United
States Renal Data Service Medicare database. The data on the
impact of glycemic control on ESRD patient survival are limited
to one retrospective15 and one single-center observational
study.22 We recently performed a primary data analysis of
glycemic control and survival on a large national ESRD
database.33 The analysis also provided new information on
patient characteristics of the type I and II diabetic subpopula-
tions with ESRD.34 This report summarizes our findings.
RESULTS
Patient characteristics are shown in Table 1. Among the
24 875 eligible patients, a total of 1371 (5.5%) had type I
diabetes and 23 504 (94.5%) had type II diabetes. Type I
study patients were significantly different from the type II
study patients, with younger age (Po0.0001), different racial
distribution with more white race (Po0.0001), longer
dialysis vintage (Po0.0016), slightly lower body surface area
(Po0.0001), and different distribution of vascular accesses
(P¼ 0.003). Type I study patients had higher serum
phosphorus levels (Po0.0016).
Type I study patients had higher mean HgbA1c values (7.5
vs 6.7%, Po0.0001). The frequency distribution of the
HgbA1c results is shown in Figure 1. For all study patients,
mean HgbA1c values were 47.0% in 35% and 48.5% in
14%; in 11.3% of patients, mean HgbA1c values were below
5%. Overall, patients with type I DM tended to have higher
HgbA1c values, with mean HgbA1c47.0% in 50% and
48.5% in 426% of type I study patients. Of the entire study
cohort, 41% were treated with insulin, 20% with oral
hypoglycemia agents, 16% with both, and 23% with neither.
For those with HgbA1co6%, 37% were on neither insulin
nor oral hypoglycemic agents.
Of the 24 744 hemodialysis patients with HgbA1c drawn,
89.6% (N¼ 22 178) had random blood glucose measure-
ments available from the previous 90 days. For the combined
type I and type II population, the mean HgbA1c was 6.77%,
and the mean random blood glucose was 168 mg/dl. A scatter
plot (not shown) generated by plotting the mean blood
Table 1 | Study patient characteristics with a breakdown into
types I and II DM (values in parenthesis are s.d.)
DM patients with HgbA1c (drawn between 1 October 2002 and
31 December2002)
Characteristics
All study
patients Type I DM Type II DM
No. of patients 24 875 1371 23 504
Age* (years) 63.7 (12.1) 49.3 (14.4) 64.5 (11.4)
% female 51.5 49.5 51.6
Race* — — —
White (%) 53.0 60.6 52.6
Black (%) 36.4 32.5 36.6
Other (%) 10.6 6.9 10.8
Vintage** (days) 1051 (951) 1172 (1.075) 1044 (943)
Body surface area* (m2) 1.86 (0.25) 1.82 (0.25) 1.86 (0.25)
% of patients on
Erythropoietin
99.0 98.7 99.0
access type*** — — —
Fistula (%) 30.0 34.4 29.7
Graft (%) 45.7 40.8 46.0
Catheter (%) 23.5 24.4 23.5
Blank (%) 0.8 0.4 0.8
HD dose (eKt/V) 1.41 (0.29) 1.41 (0.32) 1.41 (0.28)
Albumin 3.82 (0.38) 3.83 (0.42) 3.81 (0.38)
Hemoglobin 11.72 (1.10) 11.71 (1.17) 11.72 (1.09)
Calcium 9.29 (0.70) 9.27 (0.73) 9.29 (0.70)
Phosphorus* 5.60 (1.44) 5.89 (1.55) 5.59 (1.44)
Creatinine 8.23 (2.67) 8.60 (2.61) 8.20 (2.67)
White blood cell count** 7.77 (2.87) 7.97 (2.39) 7.76 (2.89)
HgbA1c (%) 6.77 (1.44) 7.49 (1.99) 6.73 (1.68)
DM, diabetes mellitus; HD, hemodialysis; HgbA1c, hemoglobin A1c.
*Po0.0001; **Po0.0016; ***P=0.003: All comparing type I vs type II DM patients
only.
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Figure 1 | Frequency distribution of HgbA1C values for all study
patients.
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glucose vs HgbA1c indicated that the HgbA1c correlated with
the mean random blood glucose levels with an R2 value of
0.3716 and a s.e. of 1.36.
The 12-month survival rates ranged from 80 to 85%
between groups, corresponding to a 15–20% unadjusted 12-
month mortality rate. Kaplan–Meier survival curves grouped
by HgbA1c levels, shown in Figure 2a, did not reach statistical
significance. This finding persisted when results from type I
and type II DM patients were separately analyzed (Figure 2b
and c). Multivariable models indicated that there were no
clear patterns between HgbA1c and death risk for all study
patients, shown in Figure 3. Despite the higher HgbA1c levels
found in type I patients, the models from our subset analyses
by DM type were similarly without any pattern (data not
shown). For patients with diabetes excluded from the study
for having no HgbA1c measured during the baseline period,
16.93% died in the subsequent year, compared to 16.15%
who died in the study population.
DISCUSSION
The incidence of ESRD attributed to DM in the US continues
to increase, linked to escalation in both the general diabetic
and diabetic CKD populations. Insulin therapies remain the
mainstay of glycemic control in ESRD patients with diabetes,
used in about 60% of patients, up to twice that of non-ESRD
Medicare patients.1 However, data on the differences between
type I and type II patients with diabetes on dialysis are not
available. Furthermore, there is currently limited evidence on
the utility of glycohemoglobin (HgbA1c) levels in ESRD as
correlated with improvement in outcomes, although such
data are available in the non-ESRD population.23,27
This is the first study to characterize a large population of
prevalent ESRD patients with diabetes. The majority were
type II patients, a proportion similar to the general diabetes
population. The smaller population of type I DM patients
was younger, more predominantly white, longer on dialysis,
had greater elevations of serum phosphorus, and had poorer
glycemic control. There were no differences in dialysis
adequacy, anemia correction, albumin levels, or serum
calcium. Classification of diabetes type in the general
population is known to be imperfect.35 For this analysis,
classification was based mainly on Medicare reporting from
Form 2728 with a few de novo diagnoses of DM (newly added
ICD-9 diagnoses) after the initiation of dialysis.
The initial analysis revealed that 50% of type I and 34% of
type II ESRD patients were above the ADA glycemic goal for
HgbA1c of 7%, itself a value well above the normal range for
nondiabetics.36 These data are better than or at least no
different from the experience in the general population,
where only 37% of adult patients with diabetes in the US are
achieving the glycemic goal.4 In the general diabetic
population, there is no HgbA1c level below which the risk
of complications does not continue to fall.27,37 Therefore, it is
not unexpected that in a recent survey on improving diabetic
ESRD outcomes, nephrologists rated better glycemic control
equal in importance to hypertension control, and more
important than lipid control.38 The latest United States Renal
Data Service report indicates that the cumulative use of
insulin and oral agents in ESRD patients with diabetes
increased between 2000 and 2003, which suggests a more
aggressive treatment approach in diabetes management.1
100a
b
c
95
90
85
80
75
0
Su
rv
iva
l (%
)
100
95
90
85
80
75
Su
rv
iva
l (%
)
100
95
90
85
80
75
Su
rv
iva
l (%
)
Months
1 2 3
5.5 5.5–6.5 6.5–7.5 7.5–8.5 >8.5
4 5 6 7 8 9 10 11 12
0
Months
1 2 3
5.5 5.5–6.5 6.5–7.5 7.5–8.5 >8.5
4 5 6 7 8 9 10 11 12
0
Months
1 2 3
5.5 5.5–6.5 6.5–7.5 7.5–8.5 >8.5
4 5 6 7 8 9 10 11 12
Figure 2 | Survival rates in HgbA1C groups. (a–c) Survival analysis
using Kaplan–Meier survival curves for all (a) study patients, and
(b) type I, and (c) type II subsets.
1.5
Ref
Unadj.
CMAdj.
CM + Lab Adj.
% of patients*
* *
*
*
* *
*
**
*
*
35
30
25
20
15
10
5
0
1.0
0.5
0.0

5.0
5–
5.5
5.5
–
6
6–
6.5
6.5
–
7
7–
7.5
7.5
–
8
8–
8.5
8.5
–
9
9–
9.5
9.5
–
10
10
–
10
.5
10
.5–
11 >1
1
N = 24 875 patients with diabetes HgbA1c (%)
%
 o
f p
a
tie
nt
s
H
az
ar
d 
ra
tio
s 
of
 d
ea
th
Figure 3 | Impact of varying levels of HgbA1c on all-cause
mortality, using Cox proportional hazard models. Data are
presented as unadjusted, case-mix adjusted, and case-mix plus
laboratory adjusted. Line indicates frequency distribution of
HgbA1c values as shown is Figure 1.
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Nonetheless, in this study, a large percentage of those with
the lowest HgbA1c values were on neither insulin nor oral
agents. Our data are the first indication that HgbA1c values
in a large cohort of hemodialysis patients with diabetes are
either similar to or range below that reported for the general
diabetic population.
HgbA1c correlated with mean random blood glucose
levels with an R2 of 0.3716 in this study. However, the s.e. of
1.36 indicated considerable variability not explained by the
random blood glucose measurements. Data from the
Diabetes Control and Complication Control indicate that
mean plasma glucose from multiple determinants of 170g/dl
correlated with a HgbA1c of 7%,39 compared with our values
of 1.68g/dl and 6.77%. This finding is interesting considering
that the random blood glucose measurements in hemo-
dialysis patients may vary considerably depending on their
dialysis shift (because the blood specimens are typically
drawn pre-dialysis), and on the confounding effect of timing
relative to food intake and medications for diabetes.
Several factors impacting on ESRD glycemic management
are known to exist, including pharmacodynamic effects of
uremia and/or the dialysis procedure on insulin and
carbohydrate metabolism, pharmacokinetic influences on
insulin and oral hypoglycemic agents used to treat hyper-
glycemia, and potential effects on HbgA1c, used as the basis
of glycemic management.40 Glycohemoglobin measurements
in this report utilized an immunoturbidimetric assay
performed in a single laboratory. Unlike high-pressure liquid
chromatography commonly used in routine laboratory
determinations of HgbA1c, the immunoturbidimetric assay
is not influenced by high urea levels or hemoglobin variants.
In the general population of patients with diabetes, the
HbA1c provides a glycemic history of the preceding 120 days,
the average red blood cell lifespan.23 However, several reports
have indicated that erythrocyte survival is reduced in ESRD,
which would be expected to lower HgbA1c levels.41
Furthermore, the widespread use of erythropoietin increases
the proportion of reticulocytes and ‘younger’ red blood cells
in circulation with less glycemic exposure time for glycosyla-
tion to occur.32,42 Current Medicare standards call for
measurement of HgbA1c every 3 months, or monthly during
dosing changes or poor glycemic control, as one of the
regular laboratory evaluations considered standard of care for
patients with diabetes, and some suggest that more frequent
testing than four times annually may be necessary in complex
patients.43 However, limited outcome-based evidence is
available to support such a recommendation in ESRD.
Issues related to poor glycemic control in the ESRD
patient with DM would be expected to include acute
management problems such as fluid overload, hyperkalemia,
and ketoacidosis, and certain chronic manifestations such as
refractory gastroparesis and malnutrition.40,44,45 Chronic
hyperglycemia has been increasingly hypothesized to con-
tribute to coronary heart disease, the major source of
morbidity and mortality, in individuals with diabetes.13
The United Kingdom Prospective Diabetes Study of patients
with type II diabetes showed a 16% reduction (P¼ 0.052) in
myocardial infarction with intensive glycemic control after 10
years of follow-up, although the overall results for cardio-
vascular outcomes were considered negative.46 The European
Prospective Investigation of Cancer and Medicine (EPIC-
Norfolk) reported a risk ratio for coronary heart disease of
1.40 for each 1% increase in HgbA1c after adjustment for
known cardiovascular risk factors.47 Other epidemiologic
cohort studies have also suggested a positive association
between HgbA1c levels and coronary risk.11
Multiple coronary factors, traditional and non-traditional,
are reported to contribute to risk of cardiovascular outcomes
in the diabetic and ESRD populations.48,49 We used an
observational epidemiologic design to evaluate the relation-
ship between glycemic control and subsequent mortality risk.
No reliable measurements of the cardiovascular risk factors
were available for analysis. Previous data on the benefit of
glycemic control for patient survival in ESRD are limited.15,22
One caveat: an inherent assumption in evaluating our results
is that HgbA1c as measured in the ESRD population,
although potentially underestimating the true glycemic state,
will nonetheless still rank glycemic control accurately for
correlation studies. This assumption is consistent with
previous small studies on HgbA1c in ESRD,19,41,50 although
the issue remains controversial and the utility of HgbA1c in
dialysis patients has not been settled.30,51
The 15–20% mortality rate in the study population is
lower than the mortality rates reported by United States
Renal Data Service for patients with diabetes.1 This finding
was expected because of the study entry criteria that required
diabetic patients to have HgbA1c values in the system within
the 90-day enrolment period, thus potentially excluding
unstable patients (e.g. incident patients or recently hospita-
lized patients) who were unable to have HgbA1c levels drawn.
In addition, incident patients beginning dialysis in 2003 were
excluded from the analysis. Kaplan–Meier survival curves did
not reveal a trend toward improved survival for lower
HgbA1c in this study.
Cox multivariable models did not reveal any statistical
correlation between HgbA1c and death risk for either case-
mix or case-mixþ laboratory-adjusted data. There are
several potential explanations for this lack of correlation.
(1) HgbA1c laboratory values were obtained for only a single
quarter. HgbA1c tracks well with fasting glucose in individual
patients in the general diabetic population,26 but time-
varying glucose levels may relate better than baseline HgbA1c
to outcomes.42 However, putative factors such as albumin,
hemoglobin, and other variables analyzed using the same
methodology show significant association with mortality.52
(2) All-cause mortality follow-up was limited to a 1-year
period following the HgbA1c determinations. It is possible
that longer term follow-up is required for the HgbA1c effect
to become apparent. This assumes that the initial HgbA1c
value is representative of long-term glycemic status and
remains consistent over time. To our knowledge, this has not
been explored in ESRD patients. (3) The study was not
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designed to adjust for known coronary heart disease risk
factors, although multiple risk factors (left ventricular
hypertrophy, anemia, vascular calcification) are present
chronically in the diabetic ESRD population. Previous studies
assessing glycemic control as a modifiable cardiovascular risk
factor have had similar limitations in adjusting for known
CAD risk factors.13 In the general population of patients with
diabetes, for example, it is understood that lowering HbgA1c
to below the 7% target may not be adequate to remove the
cardiovascular risk associated with hyperglycemia. Patients
with diabetes whose A1c levels are between 5 and 6.9% are
still at 2.5 more likely to die of cardiovascular disease than
those below 5%.47 (4) Other metabolic abnormalities
including those specific to ESRD accompany the diabetic
ESRD condition and may exert significantly more powerful
effects on mortal risk than that of poor glycemic control. The
recently reported failure of statin treatment to impact on
outcomes in ESRD patients with diabetes supports the
multifactorial nature of cardiovascular disease in this
population.53
As a corollary to no. 4 above, it is also possible that the
microvascular and macrovascular disease is so far advanced
in ESRD patients that improved glycemic control may no
longer be as dominant an influence on mortal risk. A recent
attempt by the Department of Veterans Affairs (VA) to
develop evidence-based clinical practice guidelines differed
from that promulgated by the ADA.54 They found the
evidence for improving outcomes that support tight glycemic
control (goal of HgbA1co7%) lacking for patients older
than 65 years or with pre-existing severe microvascular
damage (e.g. proliferative retinopathy, renal insufficiency,
neuropathy) who were excluded from the definitive trials.
Furthermore, the evidence base best supports stringent
glycemic control for patients with extended life expectancy.55
The VA panel recommended that HgbA1c target beo8% for
patients with pre-existing microvascular comorbidity and life
expectancy of 5–15 years and a target of HgbA1co9% for
patients with end-stage vascular disease and advanced age
with life expectancy o5 years,54 with a goal of limiting the
incidence of severe hyperglycemia while concomitantly
avoiding the risk of hypoglycemia. A recent study found
that the incidence of hypoglycemia in ESRD patients with
diabetes on insulin increased when they initiated dialysis
therapy, when compared to the pre-dialysis period.56 Insulin
requirements dropped by 29% associated with declining
residual kidney function. Apart from the changes in biologic
half-life of insulin and oral hypoglycemic agents in ESRD,
factors such as decreased appetite, inconsistent food intake,
decreased vision, declining manual dexterity, and/or sub-
clinical decline in cognitive function may place dialysis
patients who are attempting tight glucose control at risk for
hypoglycemia.
HgbA1c is the gold standard for evaluating risk of
complications in patients with diabetes. Further research
will be required to explore the value of HgbA1c or other
glycemic markers and mortality in diabetic ESRD. Single
measurements may not adequately reflect glycemic control
for previous periods, and provide no data on glycemic
control during the actual period of mortality assessment. In
the UKPDS, for example, the updated mean HgbA1c more
strongly related to increased risk of myocardial infarction
than did the baseline HgbA1c.46 Other studies have linked
cardiovascular mortality with 2-h post-prandial glucose
levels.57 Finally, the pathological effects of chronic hyper-
glycemia on vascular tissues may occur through pathways
that do not correlate with current markers of glycemic
exposure. It is possible that the correlation of HgbA1c levels
with more immediate outcomes such as quality of life,
hospitalization, and/or specific crises such as the occurrence
of severe hypoglycemia or hyperglycemia may be reasonable
targets for future research.
CONCLUSION
The study found that only 72% of ESRD patients with
diabetes were tested with HgbA1c within a 3-month period,
in a national database of patients on dialysis. The average
HgbA1c and the proportion of patients that did not meet the
ADA guideline targets were either lower than or similar to the
general population. The study found no correlation between
HgbA1c levels and subsequent 12-month mortality risk in
ESRD patients, either singly or when adjusted for case mix
and laboratory variables. Clinical practice recommendations
by the ADA acknowledge differences in the risks and benefits
of glycemic targets for individual patients.5 It is prudent to
individualize the HgbA1c target in ESRD patients, perhaps
becoming less stringent based on age, comorbidity, life
expectancy, and the presence of risk factors for the
occurrence of hypoglycemia. More studies are needed in
CKD and ESRD patients in order to refine evidence-based
recommendations for the appropriate application of tests
(such as HgbA1c) that are currently used to define glycemic
control. Similarly, more studies are needed to determine
evidence-based treatment goals for glycemic control in this
patient population.
MATERIALS AND METHODS
Patients were drawn from 76.178 ESRD patients treated with
hemodialysis at Fresenius Medical Care, North America between
1 October and 31 December 2002. Of 38.701 patients with DM
(50.8%), 13.827 (35.7%) were excluded for having no HgbA1C
measured during the 3-month baseline period. A total of 28.159
patients had HgbA1C tests done, including 3.284 non-diabetics.
Among the patients with DM, 24.875 were still being treated by
hemodialysis and in the database as of 1 January 2003 (i.e. not
transferred or discharged). These 24,875 hemodialysis patients with
diabetes and with at least one HgbA1c value drawn from 1 October
to 31 December 2002 and surviving into 1 January 2003 formed the
study cohort.
The diagnosis of DM was based on either diabetic cause of ESRD
or on reporting of diabetes as a comorbidity diagnosis before
1 January 2003. Seventy-five percent of the 24 875 patients with
diabetes had diabetes as the cause of their kidney disease based on
the Medicare 2728 form. The investigators had no influence over the
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frequency of HgbA1c determinations, which was decided by the
patient’s nephrologist. All HgbA1c values were measured using
the Roche Cobar Integra 800 whole-blood immunoturbidimetric
assay (standardized according to the Diabetes Complications
Control Trial/National Glycohemoglobin Standardization Program)
performed by a single laboratory (Spectra Laboratories, Rockleigh,
NJ, USA). The normal HgbA1c range by the assay was 4.5–5.7%.
Patient demographic and case-mix variables were collected as of
31 December 2002. These included diabetes type (type I or II), age,
gender, race, dialysis vintage, body surface area (from height and
weight), vascular access type (native fistula, graft, or catheter), and
the presence or absence of ethropoietin use within the prior 180
days. All available laboratory results for the 1 October–31 December
2002 for HgbA1c, eKt/V, hemoglobin, albumin, creatinine, calcium,
and phosphorus were collected, and the 3-month average value was
used for each patient in the analyses. In addition, all available
random blood glucose measurements on patients with HgbA1c
obtained in the last quarter of 2002, drawn within the previous 90
days from the date of the HgbA1c, were analyzed. Most patients
(75.8%) had three or more determinations. All-cause mortality data
as the final outcome were collected for the 12-month follow-up
period from 1 January to 31 December 2003.
The patient variables were grouped into three categories: all
study patients; and type I and type II DM subsets. Data for
continuous variables are presented as mean7s.d. Demographic
and clinical characteristics were compared between groups using
w2 tests for categorical variables and unpaired t-tests for
continuous variables. Kaplan–Meier curves were constructed
for survival analysis, and Cox proportional hazard models were
used to compare the impact on mortality by varying levels of
HgbA1c. The multivariable models are presented as case mix (age,
gender, etc) and case mixþ laboratory-adjusted results. The HgbA1c
reference range used for all analyses was 6.5–7.0%, consistent
with the ADA recommendation to keep HgbA1c below 7%. All
statistical analyses were performed using SAS software version 9.2
(Cary, NC, USA).
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